for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Anavex Life Sciences Corp

AVXL.OQ

Latest Trade

3.53USD

Change

0.22(+6.65%)

Volume

308,201

Today's Range

3.26

 - 

3.53

52 Week Range

1.25

 - 

4.08

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
3.31
Open
3.30
Volume
308,201
3M AVG Volume
10.44
Today's High
3.53
Today's Low
3.26
52 Week High
4.08
52 Week Low
1.25
Shares Out (MIL)
52.65
Market Cap (MIL)
185.86
Forward P/E
-5.74
Dividend (Yield %)
--

Next Event

Anavex Life Sciences Corp at Cantor Fitzgerald Global Healthcare Conference

Latest Developments

More

Anavex Life Sciences Reports Fiscal 2019 Third Quarter Financial Results And Provides Clinical Study Updates

Anavex Life Sciences Files For Mixed Shelf Of Up To $250 Mln

Anavex Life Sciences Corp Files Prospectus Supplement Relates To Issuance, Sale Of Up To $21.2 Mln In Common Shares

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Anavex Life Sciences Corp

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases, including drug candidates to treat Alzheimer's disease (AD), other central nervous system (CNS) diseases, pain and various types of cancer. Its research and development pipeline includes a clinical drug candidate and various compounds in different stages of pre-clinical study. Its product pipeline also includes ANAVEX 2-73, ANAVEX 3-71, ANAVEX 1-41, ANAVEX 1037 and ANAVEX 1066. The Company's SIGMACEPTOR Discovery Platform produces small molecule drug candidates with modes of action, based on its understanding of sigma receptors. ANAVEX 1-41 is a sigma-1 agonist. ANAVEX 1066 is a mixed sigma-1/sigma-2 ligand. As of September 30, 2016, the Company had not generated any revenues from its operations.

Industry

Biotechnology & Drugs

Contact Info

51 W 52nd St Fl 7th

+1.800.6893939

https://www.anavex.com

Executive Leadership

Christopher U. Missling

President, Chief Executive Officer, Secretary, Director

Sandra Boenisch

Principal Financial Officer, Treasurer

Stephan Toutain

Senior Vice President - Operations

Walter Kaufmann

Chief Medical Officer

Peter D.O. Donhauser

Director

Key Stats

1.50 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2019(E)

0.0K
EPS (USD)

2016

-0.420

2017

-0.330

2018

-0.390

2019(E)

-0.615
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
10.31
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-136.88
Return on Equity (TTM)
-115.70

Latest News

BRIEF-Anavex Life Sciences Reports Q2 Loss Per Share Of $0.11

* ANAVEX LIFE SCIENCES REPORTS FISCAL SECOND QUARTER 2018 FINANCIAL RESULTS

BRIEF-Anavex Life Sciences To Initiate Phase 2 Study Of Anavex®2-73 In Parkinson’S Disease Dementia

* ANAVEX LIFE SCIENCES TO INITIATE PHASE 2 STUDY OF ANAVEX®2-73 IN PARKINSON’S DISEASE DEMENTIA AND PROVIDES CLINICAL STUDY UPDATE FOR ANAVEX®2-73 IN RETT SYNDROME

BRIEF-Anavex Life Sciences reports PK and PD data from Phase 2a trial of ANAVEX2-73

* Anavex Life Sciences reports PK and PD data from Phase 2a trial of ANAVEX2-73 in mild-to-moderate Alzheimer’s Disease patients

BRIEF-Anavex reports Q3 loss per share of $0.09

* Q3 loss per share $0.09 Source text for Eikon: Further company coverage:

BRIEF-Anavex Q2 loss per share $0.04

* Anavex reports fiscal second quarter 2017 financial results

BRIEF-Anavex Life Sciences provides update on lawsuit

* Anavex life sciences corp reports dismissal of appeal in cortina lawsuit without payment of any fees or costs by company Source text for Eikon: Further company coverage:

BRIEF-Anavex reports Q1 loss per share $0.08

* Says it is now able to initiate subsequent placebo-controlled efficacy and safety trials for Anavex 2-73 in Alzheimer's and Parkinson's disease as well as rett syndrome Source text for Eikon: Further company coverage:

BRIEF-Anavex life sciences appoints three distinguished researchers to scientific advisory board

* Anavex life sciences appoints three distinguished researchers to scientific advisory board Source text for Eikon: Further company coverage:

BRIEF-Anavex Life Sciences novel sigma-1 / sigma-2 ligand shows encouraging results as an analgesic in animal models of neuropathic and visceral pain

* Anavex Life Sciences novel sigma-1 / sigma-2 ligand shows encouraging results as an analgesic in animal models of neuropathic and visceral pain Source text for Eikon: Further company coverage:

BRIEF-Anavex and Ariana collaborate over Alzheimer's and Parkinson's clinical development programs

* Anavex Life Sciences and Ariana Pharma collaborate to accelerate timelines and improve efficiency of Alzheimer's and Parkinson's clinical development programs Source text for Eikon: Further company coverage:

BRIEF-Anavex signs material transfer agreement with Biogen

* Signed material transfer agreement with Biogen under which Biogen will test Anavex's lead drug candidate, Anavex 2-73 Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up